G1 Therapeutics ( NASDAQ:GTHX – Get Free Report ) ‘s stock had its 'outperform' rating reissued by research analysts at Wedbush in a report released on Thursday, Benzinga reports. They currently have a $5.00 target price on the stock. Wedbush's price objective would suggest a potential upside of 130.41% from the stock's current price. Separately, Needham & Company LLC reduced their price target on shares of G1 Therapeutics from $18.00 to $14.00 and set a 'buy' rating for the company in a report on Wednesday.

https://www.dailypolitical.com/2023/08/05/wedbush-reiterates-outperform-rating-for-g1-therapeutics-nasdaqgthx.html

#dailypolitical